Table 1 Clinical and pathological patient characteristics of the TCGA and CPC-GENE cohorts
| Â | Entire cohort | CR/IDC positive | CR/IDC negative | |||
|---|---|---|---|---|---|---|
TCGA | CPC-GENE | TCGA | CPC-GENE | TCGA | CPC-GENE | |
Mean (IQR) or N (%) | Mean (IQR) or N (%) | Mean (IQR) or N (%) | ||||
Number | 260 (100%) | 199 (100%) | 80 (31%) | 76 (38%) | 180 (69%) | 123 (62%) |
Age (years) | 60 (56–66) | 61 (57–66) | 61 (57–66) | 61 (58–66) | 60 (55–70) | 61 (57–64) |
PSA (ng/mL) | 10 (5.1–11) | 7.6 (4.8–9.3) | 12 (6.4–15) | 8.1 (4.9–10) | 9.5 (4.6–9.7) | 7.3 (4.8–9.1) |
GS | ||||||
 3 + 3 | 96 (37%) | 69 (35%) | 0 | 0 | 96 (53%) | 69 (56%) |
 3 + 4 | 78 (30%) | 95 (48%) | 27 (34%) | 44 (58%) | 51 (28%) | 51 (41%) |
 4 + 3 | 39 (15%) | 25 (12%) | 22 (27%) | 22 (29%) | 17 (10%) | 3 (3%) |
 8 | 19 (7.3%) | 9 (4%) | 17 (21%) | 9 (12%) | 2 (1%) | 0 |
 9–10 | 28 (11%) | 1 (1%) | 14 (18%) | 1 (1%) | 14 (8%) | 0 |
pT stage | ||||||
 T2 | 112 (43%) | 84 (42%) | 20 (25%) | 20 (26%) | 92 (51%) | 64 (52%) |
 T3a | 80 (31%) | 58 (29%) | 28 (35%) | 26 (35%) | 52 (29%) | 32 (26%) |
 T3b | 55 (21%) | 15 (8%) | 31 (39%) | 10 (13%) | 24 (13%) | 5 (4%) |
 T4 | 4 (2%) | 0 | 1 (1%) | 0 | 3 (2%) | 0 |
 Tx | 9 (3%) | 42 (21%) | 0 | 20 (26%) | 9 (5%) | 22 (18%) |